KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Net (2017 - 2025)

Amneal Pharmaceuticals has reported Receivables - Net over the past 9 years, most recently at $413000.0 for Q4 2025.

  • Quarterly results put Receivables - Net at $413000.0 for Q4 2025, down 99.95% from a year ago — trailing twelve months through Dec 2025 was $413000.0 (down 99.95% YoY), and the annual figure for FY2025 was $413000.0, down 99.95%.
  • Receivables - Net for Q4 2025 was $413000.0 at Amneal Pharmaceuticals, down from $1.4 billion in the prior quarter.
  • Over the last five years, Receivables - Net for AMRX hit a ceiling of $1.4 billion in Q3 2025 and a floor of $2000.0 in Q4 2022.
  • Median Receivables - Net over the past 5 years was $675.7 million (2021), compared with a mean of $727.7 million.
  • Biggest five-year swings in Receivables - Net: crashed 100.0% in 2022 and later surged 81213.52% in 2024.
  • Amneal Pharmaceuticals' Receivables - Net stood at $662.6 million in 2021, then crashed by 100.0% to $2000.0 in 2022, then skyrocketed by 47600.0% to $954000.0 in 2023, then surged by 81213.52% to $775.7 million in 2024, then plummeted by 99.95% to $413000.0 in 2025.
  • The last three reported values for Receivables - Net were $413000.0 (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.